Embed
Share
{{textForToggleButton('117576079')}}
FDA Hearing On Proposal To Withdraw Approval For Avastin
Kimberly Jewett, director of collaboration and outreach at MyLife.org also a breast cancer patient, testifies in favor of Avastin during a Food and Drug Administration (FDA) hearing in Silver Spring, Maryland, U.S., on Tuesday, June 28, 2011. Breast-cancer patients and their families urged U.S. regulators to back down from a plan to withdraw approval for Roche Holding AG's Avastin, saying the treatment offered significant benefits for some women. Photographer: Joshua Roberts/Bloomberg via Getty Images
{{::t('rf_licenses_include')}}
{{::t('gi_rf_includes')}}
- {{ t('unlimited_print_runs')}}
- {{ t('comprehensive_protection')}}
{{::t('common_uses')}}
{{::t('forbidden_uses')}}
{{::t('esl_standard_editorial_rights')}}
{{::t('standard_rights')}}
{{::t('subject_to_content_license_agreement')}}
{{selectAgreementHeader}}
{{sizeData()}}
{{t('format_requires_conversion')}}{{t('format_requires_conversion_tooltip')}} | {{formatPrice(size.price)}}{{formatPrice(size.discountPrice || size.price)}}{{size.discountPrice || size.price}} |
{{t('new_bang_all_caps')}}
{{::t('editorial_use_only_label')}}
{{::t('editorial_use_only_tooltip')}}
Restrictions:Contact your local office for all commercial or promotional uses.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg's prior written consent.
Credit:Bloomberg / Contributor
Editorial #:117576079
Collection:Bloomberg
Date created:June 28, 2011
License type:Rights-managedRelease info:Not released. More information
Source:Bloomberg
Object name:FDA AVASTIN
Max file size:3500 x 2438 px (11.67 x 8.13 in) - 300 dpi - 1.73 MB